Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-05-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the Annual General Meeting (AGM) of Hangzhou Anxu Biotechnology Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2021 annual report, financial budget, profit distribution, audit firm reappointment, and remuneration plans. The document also includes legal witness statements confirming the legality and validity of the meeting and resolutions. The content is focused on the voting results and resolutions passed at the AGM rather than the full annual report or financial statements themselves. The document length is about 5780 characters, which is sufficient to contain detailed voting results and resolutions. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-18 Chinese
上海锦天城（杭州）律师事务所关于杭州安旭生物科技股份有限公司2021年年度股东大会法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of Hangzhou Anxu Biotechnology Co., Ltd. It details the legality of the AGM's convening, attendance, agenda, and voting results. The content focuses on the procedures and validation of the AGM rather than the full annual report or financial statements. The document length is 4562 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full report. The document is not the annual report itself but a legal opinion on the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including legal opinions related to the meeting.
2022-05-18 Chinese
安旭生物关于公司相关检测产品获得医疗器械注册证的自愿披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Hangzhou Anxu Biotechnology Co., Ltd. regarding the receipt of medical device registration certificates for several testing products. It details product certification information from Australia and the EU, the impact on the company, and risk warnings. The document is short (1580 characters) and serves as an announcement of regulatory approvals rather than a financial report or detailed operational report. It does not contain financial data, management discussion, or regulatory filings related to financial performance. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product certifications and company disclosures that do not fit other specific categories.
2022-05-12 Chinese
安旭生物2021年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the 2021 Annual General Meeting (AGM) materials for Hangzhou Anxu Biotechnology Co., Ltd. It includes detailed agenda items for the 2021 AGM, such as the 2021 Board of Directors work report, supervisory board report, annual report and summary, financial budget report, profit distribution plan, audit firm reappointment, and remuneration plans. The content is comprehensive and clearly intended as meeting materials for the AGM, including voting procedures, meeting rules, and detailed reports to be discussed at the AGM. There is no indication that this is a full annual report (10-K) or a simple announcement of the meeting or voting results. The document is lengthy (15,000 characters) and contains substantive content for the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2022-05-10 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司首次公开发行网下配售限售股上市流通的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from Minsheng Securities regarding the special verification opinion on the listing and circulation of restricted shares from the initial public offering (IPO) of Hangzhou Anxu Biotechnology Co., Ltd. It references regulatory approvals, specific share quantities, lock-up periods, and shareholder commitments related to the IPO and subsequent listing on the Shanghai Stock Exchange Sci-Tech Innovation Board (科创板). The content focuses on the verification and compliance of restricted shares becoming tradable after the lock-up period, including detailed shareholder data and share counts. This type of document is a regulatory compliance and verification report related to share listing and circulation, not a financial report, earnings release, or management discussion. It is not an announcement of voting results, board changes, or capital changes. It is a specialized regulatory verification report concerning share circulation post-IPO. Given the detailed regulatory and compliance nature, and that it does not fit into other categories like Annual Report, Earnings Release, or Capital Update, the best fitting category is Regulatory Filings (RNS). The document is substantive and not a mere announcement, so it is not Report Publication Announcement (RPA). Confidence is high due to the clear regulatory compliance focus and detailed shareholder data.
2022-05-09 Chinese
安旭生物首次公开发行网下配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is titled as an announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) offline placement. It details the number of shares becoming tradable, the lock-up period, shareholder commitments, and includes a detailed list of shareholders and share quantities. The document references regulatory approval from the China Securities Regulatory Commission and compliance with stock exchange rules. It is not a financial report, earnings release, or management discussion, but rather an official announcement about the unlocking and listing of restricted shares for trading. This fits the category of Share Issue/Capital Change (SHA), as it concerns the change in share capital availability and circulation status after IPO restrictions expire.
2022-05-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.